Australian bat lyssavirus: implications for public health.

Autor: Francis JR; Department of Paediatrics, Royal Darwin Hospital, Darwin, NT, Australia. josh.francis@nt.gov.au., McCall BJ; Metro South Public Health Unit, Queensland Health, Brisbane, QLD, Australia., Hutchinson P; Darling Downs Public Health Unit, Queensland Health, Toowoomba, QLD, Australia., Powell J; Mater Health Services, Brisbane, QLD, Australia., Vaska VL; Mater Pathology, Brisbane, QLD, Australia., Nourse C; Mater Health Services, Brisbane, QLD, Australia.
Jazyk: angličtina
Zdroj: The Medical journal of Australia [Med J Aust] 2014 Dec 11; Vol. 201 (11), pp. 647-9.
DOI: 10.5694/mja13.00261
Abstrakt: Australian bat lyssavirus (ABLV) infection in humans is rare but fatal, with no proven effective therapy. ABLV infection can be prevented by administration of a post-exposure prophylaxis regimen of human rabies immunoglobulin and rabies vaccine. All Australian bats (flying foxes and microbats) should be considered to be carrying ABLV unless proven otherwise. Any bat-related injury (bite, scratch or mucosal exposure to bat saliva or neural tissue) should be notified immediately to the relevant public health unit - no matter how small the injury or how long ago it occurred. Human-to-human transmission of ABLV has not been reported but is theoretically possible. Standard infection control precautions should be employed when managing patients with suspected or confirmed ABLV infection.
Databáze: MEDLINE
Externí odkaz: